TrialThe oncologist2022

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.

Toni K Choueiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.